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A. Michael Lincoff, MDSEE PAGE 1574I mproved antithrombotic therapies have remark-ably enhanced the safety and efﬁcacy of percuta-neous coronary intervention (PCI). Although
rates of short-term ischemic complications were as
high as 10% to 13% in patients receiving only aspirin
and intraprocedural heparin during PCI, addition of
platelet glycoprotein IIb/IIIa inhibitors (GPI) reduced
that risk by as much as 50% and long-term mortality
by nearly 20% (1,2). Intense platelet inhibition
produced by these agents, however, resulted in
increased rates of bleeding complications (3,4), asso-
ciated with prolonged hospitalizations, increased
costs, and late mortality (5). Nevertheless, GPIs
became widely accepted into the standard of care
during PCI, especially in the setting of acute coronary
syndromes (ACS), where the clinical beneﬁt of these
agents seemed particularly noteworthy.
But interventional practice and pharmacotherapies
continued to evolve, with development of reﬁned,
thinner-strut stent designs associated with less
thrombogenicity (6), early administration of platelet
ADP P2Y12 receptor antagonists to patients with ACS
or undergoing PCI (7), and introduction of the more
potent P2Y12 inhibitors ticagrelor and prasugrel (8,9).
In this context, the balance of beneﬁt versus risk with
GPI became less clear. In a randomized trial among
patients who had received clopidogrel before elective
PCI, GPI did not reduce ischemic complications
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for Amgen.higher-risk patients with ACS showed efﬁcacy of
GPI in reducing ischemic complications of PCI (11),
but also showed that these agents could be reserved
for selective use in those patients with substantial
thrombus burden, high-risk anatomy, or intra-
procedural complications (3). A series of trials were
then carried out among patients undergoing PCI for
elective indications or ACS, demonstrating that sub-
stitution of the direct thrombin inhibitor bivalirudin
for the combination of heparin plus a GPI consistently
reduced bleeding complications by as much as 40%
(12–14). Neither ischemic events nor long-term mor-
tality was increased with bivalirudin in those trials,
and this agent eventually supplanted heparin and
GPI during PCI for many patients.In this issue of JACC: Cardiovascular Interventions,
Saﬂey et al. (15) report the results of an observational
study examining the efﬁcacy and safety of GPI in the
contemporary interventional management of patients
with ACS. They performed a retrospective analysis of
data obtained from the National Cardiovascular Data
Registry of more than 970,000 patients undergoing
PCI for an ACS between 2009 and 2011. Approximately
one-third of these patients received GPI, and the as-
sociation between GPI use and in-hospital mortality
and major bleeding was assessed. Three different
methods were used to adjust for potential bias in the
application of GPI: multivariable logistic regression,
propensity matching, and instrumental variable
analysis. In the adjusted analyses, GPI use was asso-
ciated with reduced mortality (relative risk ranging
from 0.72 to 0.90) and increased major bleeding (rela-
tive risk ranging from 1.53 to 1.93). The authors
concluded that “in the modern era of PCI, there may
still be a role for judicious use of GPI.”
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1584The principal concern with this study, of course,
is the observational nature of the analysis. Without
randomization, any observed associations between
the treatment variable (GPI) and outcome cannot be
proven to be causative. Nevertheless, the statistical
methods are sophisticated and appropriate, and the
authors have extensive experience in rigorous anal-
yses of large-scale databases. That all 3 methods of
statistical adjustment resulted in very similar hazard
ratios for the mortality and bleeding endpoints sug-
gests that the ﬁndings are robust. Thus, although
acknowledging that all nonrandomized comparisons
seeking to establish causation or outcome with a
particular therapy must be considered exploratory,
it is reasonable to regard the methodology as valid
and the results as likely reﬂective of outcome of
randomized trials.
The results of this study, then, would seem to
suggest a remarkable beneﬁt of GPI in patients un-
dergoing PCI for ACS, with 10% to 28% reductions in
mortality that would far outweigh in importance the
50% to 90% increases in major bleeding. It is not
clear, though, what information this analysis pro-
vides beyond that of randomized trials that have
already been performed. The authors provide the
rationale that randomized trials were powered to show
reductions in “myonecrosis rather thanmortality” and
enrolled “low to moderate risk patients.to limit
bleeding complications.” Yet pooled analyses of ran-
domized trials have been published with sufﬁcient
statistical power to assess mortality (2), and the
authors of the current study have provided little in-
formation to contrast the risk proﬁle of their patients
with those in the large-scale randomized trials.
Moreover, examination of relevant subgroups in
this study suggests that the results are largely
conﬁrmatory and provide limited new insights into
the use of GPI in contemporary practice. Perhaps
most importantly, GPI was observed to reduce mor-
tality in patients receiving heparin, but not those
treated with bivalirudin. This ﬁnding is completely
concordant with outcomes of the multiple random-
ized trials that showed bivalirudin to produce similar
ischemic outcomes, including mortality, as doesheparin with GPI (12–14). Thus, the current study does
not modify or expand the indications for GPI relative
to bivalirudin. A puzzling ﬁnding of this study is
that mortality was reduced by GPI among patients
with ST-segment elevation myocardial infarction, but
increased in those without ST-segment elevation.
This observation lacks biological plausibility and
raises concerns regarding unadjusted confounding
of these observational data. Finally, the results
provide little information regarding 2 important
recent advances in interventional practice. Only 5%
to 7% of patients in this cohort had radial artery
access, and the ﬁndings may thus not be reﬂective
of current practice where rates of radial access are
substantially higher. Only 11% to 12% of patients
received third-generation P2Y12 inhibitors, despite
the superiority of these agents among patients with
ACS (8,9), and results were not reported for this
important subgroup. Appropriate utilization of third-
generation P2Y12 antagonists may well attenuate the
incremental beneﬁt of GPI with lower risk of bleeding.
Thus, although one can hardly disagree with the
authors’ conservative conclusion that there may be
a role for “judicious use” of GPI in contemporary
coronary intervention, selection of pharmacotherapy
must continue to be guided by the ﬁndings of the
randomized trials. GPI provides superior protection
against ischemic events in patients undergoing PCI
for ACS, particularly those patients at high risk for
ischemic events, when compared with heparin alone
with clopidogrel. This beneﬁt was observed in ran-
domized trials published as recently as 2006 (11) and
is corroborated by the current observational database
analysis. But bleeding is increased with GPI, and
alternative approaches exist. There is no advantage of
GPI and heparin over bivalirudin, and the latter
strategy reduces bleeding. The role of GPI in combi-
nation with ticagrelor or prasugrel for ACS remains to
be deﬁned.
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